PCC 2.22% 22.0¢ probiomics limited

biotech double and sector rotation wATCH Sirtex Medical SRX...

  1. 2,773 Posts.
    biotech double and sector rotation wATCH Sirtex Medical SRX experiencing 150-200% growth, FDA approved , profitable,expanding uses for its Sir spheres,pharma partnerships with big bio-pharma and at 12x next years earnings and PEG raio of 12/200=.06 which is very undervalued considering most proftable biotechs are at 1-2 PEG ratios. Looking for double in next few weeks to $4.50-5.
 
watchlist Created with Sketch. Add PCC (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.